Want to see SLS full AI Analyst Report?
Top Page
SELLAS Life Sciences Group
(NASDAQ:SLS)
Select Model
Select Model
Rating:47Neutral
Price Target:
$11.00
▼(-2.83% Downside)
Action:Reiterated
Date:07/28/26
The score is primarily held down by weak financial performance (no meaningful revenue, persistent losses, and continued cash burn) despite a relatively low-debt balance sheet. Technicals are mixed with longer-term support but short-term softness, while valuation is constrained by negative earnings and no dividend support. Recent corporate events add both funding support (positive) and legal/arbitration overhang plus dilution considerations (negative).
Positive Factors
Balance sheet strength
SELLAS’s minimal debt and materially improved equity provide durable financial flexibility for a clinical-stage biotech. Low leverage reduces refinancing risk and interest burden, allowing management to prioritize R&D and partnerships rather than near-term debt servicing, supporting programs over the next several quarters.
Negative Factors
Lack of revenue & persistent losses
SELLAS remains a pre-revenue, clinical-stage company with sustained net losses (~$29.5M TTM). Without a meaningful revenue base, the firm cannot self-fund operating costs, leaving long-term sustainability dependent on successful trials, partnerships, or recurring external financing to bridge toward commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
SELLAS’s minimal debt and materially improved equity provide durable financial flexibility for a clinical-stage biotech. Low leverage reduces refinancing risk and interest burden, allowing management to prioritize R&D and partnerships rather than near-term debt servicing, supporting programs over the next several quarters.
Read all positive factors
SELLAS Life Sciences Group (SLS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.86B
Dividend YieldN/A
Average Volume (3M)9.61M
Price to Earnings (P/E)―
Beta (1Y)0.69
Revenue GrowthN/A
EPS Growth41.60%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.23
Shares Outstanding186,032,580
10 Day Avg. Volume6,840,242
30 Day Avg. Volume9,611,115
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)5.80
Price to Sales (P/S)0.00
P/FCF Ratio-14.48
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$27.50Price Target Upside142.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$36.13M
SELLAS Life Sciences Group Business Overview & Revenue Model
Company Description
SELLAS Life Sciences Group, Inc. (SLS) is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies. The company’s pipeline is centered on peptide-based immunotherapies and related oncology programs, with its lead cli...
How the Company Makes Money
null...
SELLAS Life Sciences Group Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 1.00M | 7.60M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 900.00K | 7.40M |
| EBITDA | -22.37M | -26.86M | 632.00K | 529.00K | -31.49M | -18.32M |
| Net Income | -29.46M | -26.86M | -30.88M | -37.34M | -41.30M | -20.70M |
Balance Sheet | ||||||
| Total Assets | 114.18M | 78.34M | 19.43M | 6.22M | 20.94M | 26.43M |
| Cash, Cash Equivalents and Short-Term Investments | 107.20M | 71.89M | 13.89M | 2.53M | 17.13M | 21.45M |
| Total Debt | 871.00K | 1.00M | 1.00M | 906.00K | 945.00K | 808.00K |
| Total Liabilities | 6.76M | 7.47M | 9.97M | 14.20M | 16.09M | 6.08M |
| Stockholders Equity | 107.41M | 70.87M | 9.46M | -7.98M | 4.85M | 20.35M |
Cash Flow | ||||||
| Free Cash Flow | -28.16M | -28.39M | -35.40M | -36.91M | -28.31M | -26.02M |
| Operating Cash Flow | -28.16M | -28.39M | -35.40M | -31.41M | -23.81M | -26.02M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -5.50M | -4.50M | 0.00 |
| Financing Cash Flow | 106.86M | 86.30M | 46.76M | 22.32M | 24.08M | 12.07M |
SELLAS Life Sciences Group Risk Analysis
SELLAS Life Sciences Group disclosed 77 risk factors in its most recent earnings report. SELLAS Life Sciences Group reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SELLAS Life Sciences Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.82B | -4.42 | -50.17% | ― | 34.26% | 23.00% | |
58 Neutral | $1.50B | -8.83 | -28.77% | ― | -23.48% | 25.73% | |
52 Neutral | $518.11M | -2.46 | -44.39% | ― | -79.06% | -397.92% | |
52 Neutral | $1.97B | -66.12 | 31.23% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.15B | -7.69 | -35.33% | ― | ― | 23.91% | |
47 Neutral | $1.86B | -43.85 | -47.12% | ― | ― | 41.60% |
* Healthcare Sector Average
SLS
SELLAS Life Sciences Group
11.81
10.19
629.01%
XNCR
Xencor
19.92
11.97
150.57%
IOVA
Iovance Biotherapeutics
4.36
1.61
58.55%
ARVN
Arvinas Holding Company
9.00
1.39
18.27%
ORIC
Oric Pharmaceuticals
13.47
3.48
34.83%
NBTX
Nanobiotix
39.52
32.57
468.63%
SELLAS Life Sciences Group Corporate Events
Business Operations and StrategyLegal Proceedings
SELLAS Life Sciences Faces Adverse Arbitration Ruling
Negative
Jul 27, 2026
On July 24, 2026, a sole arbitrator at the Hong Kong International Arbitration Centre dismissed SELLAS Life Sciences Group’s claims in a binding arbitration against 3D Medicines, Inc., and ordered SELLAS to pay about $1.0 million of 3D Medic...
Business Operations and StrategyExecutive/Board Changes
SELLAS Updates Executive Severance and Change-of-Control Terms
Neutral
Jun 25, 2026
On June 24, 2026, SELLAS Life Sciences Group amended the employment and severance arrangements of its senior leadership, including President and CEO Dr. Angelos Stergiou, CFO John Burns and Chief Development Officer Dr. Dragan Cicic, after a board...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
SELLAS Stockholders Approve Governance and Equity Plan Changes
Positive
Jun 18, 2026
On June 16, 2026, SELLAS Life Sciences Group, Inc. held its Annual Meeting of Stockholders, with approximately 62.59% of outstanding shares represented, and re-elected Class I directors Robert Van Nostrand and Jane Wasman to serve until the 2029 a...
Financial DisclosuresPrivate Placements and Financing
SELLAS Life Sciences boosts liquidity through warrant exercises
Positive
Jun 2, 2026
SELLAS Life Sciences Group, Inc. reported that as of March 31, 2026, it held $107.1 million in cash and cash equivalents, providing a snapshot of its financial resources at the end of the first quarter of 2026. The company subsequently strengthene...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.